Perry C. Siatis - 21 Feb 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, GC AND SECRETARY
Signature
Steven L. Scrogham, attorney-in-fact for Perry C. Siatis
Issuer symbol
ABBV
Transactions as of
21 Feb 2023
Net transactions value
-$1,112,178
Form type
4
Filing time
22 Feb 2023, 16:00:38 UTC
Previous filing
21 Feb 2023
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $688,534 +7,364 +23% $93.50 39,532 21 Feb 2023 Direct
transaction ABBV Common Stock, $0.01 par value Sale $517,155 -3,431 -8.7% $150.73 36,101 21 Feb 2023 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $595,024 -3,933 -11% $151.29 32,168 21 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to buy) Options Exercise $688,534 -7,364 -100% $93.50 0 21 Feb 2023 Common Stock 7,364 $93.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.49, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).